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Selective sweep for an enhancer involucrin allele
identifies skin barrier adaptation out of Africa
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The genetic modules that contribute to human evolution are poorly understood. Here we
investigate positive selection in the Epidermal Differentiation Complex locus for skin barrier
adaptation in diverse HapMap human populations (CEU, JPT/CHB, and YRI). Using Com-
posite of Multiple Signals and iSAFE, we identify selective sweeps for LCE1A-SMCP and
involucrin (IVL) haplotypes associated with human migration out-of-Africa, reaching near
fixation in European populations. CEU-IVL is associated with increased IVL expression and a
known epidermis-specific enhancer. CRISPR/Cas9 deletion of the orthologous mouse
enhancer in vivo reveals a functional requirement for the enhancer to regulate Ivl expression
in cis. Reporter assays confirm increased regulatory and additive enhancer effects of CEU-
specific polymorphisms identified at predicted IRF1 and NFIC binding sites in the IVL enhancer
(rs4845327) and its promoter (rs1854779). Together, our results identify a selective sweep
for a cis regulatory module for CEU-IVL, highlighting human skin barrier evolution for
increased IVL expression out-of-Africa.
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Modern humans (Homo sapiens) have evolved by adapt-ing to local environments and niches, under constantpressure to survive1. Our current understanding of
human evolution has been founded on visual phenotypic changes
and the underlying genetic variation. However, whole-genome
sequencing and downstream methodology have facilitated a
reverse genomics approach, allowing researchers to more accu-
rately pinpoint significant genetic differences and thus reveal
additional adaptive traits2,3. In particular, the availability of
multiple and diverse human genomes has revolutionized the field,
enabling the identification of loci undergoing selection in differ-
ent populations and their impact on human health3,4. Here we
investigate human skin barrier adaptation by examining sig-
natures of positive selection within the epidermal differentiation
complex (EDC) locus from a diverse set of human genomes. The
EDC (located on human 1q21, mouse 3q) exhibited the highest
rate of non-synonymous substitutions in the human genome and
was ranked as the most rapidly diverging gene cluster in the
human–chimp genome comparison5. The EDC spans approxi-
mately 1.6 Mb and contains 64 genes representing four gene
families, including the filaggrin (FLG)-like or SFTP (S100-fused-
type protein), late cornified envelope (LCE), small proline repeat-
rich (SPRR), and S100-domain (S100) family members6,7. The
expression of many of these EDC genes is a hallmark feature of
the terminally differentiated epidermal cells (keratinocytes) that
comprise the interfollicular epidermis and form the first line of
defense at the skin surface8. Many EDC proteins, including
involucrin (IVL) and many SPRRs and LCEs, are covalently
cross-linked to form the cornified envelope that surrounds the
keratinocyte8. Identification of EDC orthologs across many
mammalian genomes9–12 led to the discovery of the observed
linearity and synteny of the EDC in both mammals and
vertebrates6,713–17. We previously identified positive selection in
the EDC for specific genes across the mammalian phylogeny, and
specifically in primates and humans18. Motivated by these studies,
we hypothesized ongoing evolution within the EDC for skin
barrier adaptation among the geographically diverse group of
modern-day human populations.
Here, we show selective sweeps for LCE1A-SMCP and IVL
haplotypes associated with human migration out-of-Africa. The
European CEU-IVL haplotype is associated with increased IVL
expression and includes an epidermis-specific enhancer. Deletion
of the enhancer in mice using CRISPR/Cas9 genome editing
results in a significant decrease in Ivl expression in cis. We
translate this new knowledge of the enhancer to regulate IVL in
humans and examine human population-specific alleles for IVL.
We find increased regulatory activity specific to CEU-IVL with an
additive effect by the enhancer that includes predicted binding for
IRF1 at enhancer rs4845327 and NFIC binding at promoter
rs1854779. Together, the findings highlight recent human skin
barrier evolution for increased IVL expression and its enhancer,
as humans migrated out-of-Africa.
Results
Selective sweeps for the CEU-LCE1A-SMCP and CEU-IVL
haplotypes out-of-Africa. We sought to determine positive
selection in the EDC using two independent algorithms, com-
posite of multiple signals (CMS)19,20 and the integrated selection
of allele favored by evolution (iSAFE)21 (Fig. 1a). CMS compre-
hensively identifies sites that are most likely to have undergone a
positive selective sweep, reporting a composite probability score
from multiple selection tests for a given SNP19. iSAFE incorpo-
rates coalescent structures surrounding regions under selective
sweep to further rank and pinpoint sites of positive selection21.
CMS scores for all EDC HapMap II SNPs were extracted for each
of the following populations: individuals from (1) Utah of Eur-
opean descent (CEU), (2) Yoruba from Ibadan, Nigeria (YRI),
and pooled Japanese in Tokyo, Japan and Han Chinese in Beijing
(JPT/CHB)22. Signals of positive selection using CMS were not
detected in YRI (false discovery rate, FDR < 0.05, Supplementary
Data 1). However, rs4511111 near HRNR was positively selected
in JPT/CHB (Fig. 1b) and is in strong linkage disequilibrium (LD)
(r2 ≥ 0.8) with the positively selected HRNR-FLG “Huxian hap-
logroup” previously reported in the Han Chinese population23
which further validates the significance of the Huxian haplogroup
sweep. By contrast, evidence of positive selection in CEU was
found in two genomic regions: rs3007674 nearby S100A11 and a
cluster of four SNPs near SMCP (rs12022319, rs4845490,
rs4845491, and rs3737861) that collectively exhibited the stron-
gest signal in CEU (3.64 ≤ CMSGN ≤ 4.75; CMSGN, genome-
normalized composite of multiple signals). Thus, our findings
using CMS identifies selective sweeps for HRNR-FLG in JPT/CHB
and near S100A11 and SMCP in CEU.
We sought to validate and refine the positively selected regions
identified by CMS using iSAFE21. iSAFE incorporates the
“shoulders” that are proximal to the region under selective sweep
and ranks the signals to further identify the favored mutation.
iSAFE scores were calculated for 1000 Genomes Project (1KGP)
Phase 3 SNPs within the EDC in YRI, JPT/CHB, and CEU
populations, with evidence of positive selection defined as an
iSAFE score greater than 0.1 (empirical p < 1 × 10−4)21. We found
no evidence of positive selection in YRI using iSAFE consistent
with the CMS negative findings (Supplementary Data 2).
However, iSAFE revealed positive selection in JPT/CHB between
LCE1F and LCE1B (rs10157301, rs1930127, and rs11804609), but
did not replicate the CMS finding for HRNR-FLG (Fig. 1c and
Supplementary Data 2). iSAFE also identified three genomic
regions under positive selection in CEU. Signals for the HRNR-
CRNN and LCE2D regions were newly discovered (Fig. 1c and
Supplementary Data 2). The HRNR-CRNN signals span multiple
genes in the S100-fused family, including HRNR, FLG, FLG2,
CRNN, and the noncoding RNA FLG-AS1. More importantly,
iSAFE validated the same SMCP region identified by CMS with
evidence of a relatively broader region under selection (Fig. 1c).
The same four CMS SNPs near SMCP were among a cluster of
iSAFE signals (13 SNPs) between LCE1B, LCE1A, and LCE6A. To
the right of this LCE1B-SMCP region, a shoulder of iSAFE signals
(7 SNPs) upstream and within IVL was also newly detected with
scores at 0.097. Similar signals were not observed in the shoulders
of other positively selected regions, suggesting either a strong
hitchhiking effect of this shoulder or perhaps a very recent driver
for the positively selected LCE1B-SMCP region. iSAFE signals
(0.095) in CEU were also detected near SPRR1B but were isolated
indicative of a relatively soft selective sweep. Thus, our iSAFE
results reveal additional findings for selective sweeps near LCE1F
and LCE1B in JPT/CHB and HRNR-CRNN and LCE2D in CEU.
iSAFE provided higher resolution and further validation of CMS
signal surrounding the LCE1B-SMCP region and elucidation of
the positively selected IVL shouldering region in CEU that we
also found to be positively selected in European 1KGP
populations, FIN (Finnish in Finland) and IBS (Iberian popula-
tion in Spain) (Supplementary Data 2 and Supplementary Fig. 1).
Together, both CMS and iSAFE findings identify population-
specific signatures of positive selection in the EDC with notable
selective sweeps that span the LCE1B-IVL region, highlighting
human evolution associated with the skin barrier.
We next determined the haplotype structure(s) for the positively
selected signals found in the LCE1B-SMCP and IVL regions in CEU
(Supplementary Data 3). The LCE1B-SMCP region is marked by a
65.2 kb haplotype, referred to as CEU-LCE1A-SMCP, whereas the
IVL region is marked by 41.2 kb haplotype including the IVL gene,
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referred to as CEU-IVL (Fig. 2a). The same haplotypes were also
found in FIN and IBS (Supplementary Data 3). As the SNPs found
in the CEU-LCE1A-SMCP and CEU-IVL haplotypes are globally
distributed, we hypothesized recent selective sweeps for CEU-
LCE1A-SMCP and CEU-IVL that correlate with an out-of-Africa
migration. To test this hypothesis, we examined the relationships
between the allele frequencies for the CEU-LCE1A-SMCP
(rs4845490-A) and CEU-IVL (rs4845327-G) haplotypes in a given
1KGP population to the population’s latitude used as a proxy for
human migration. We found a direct and positive correlation for
the SNP frequency to northern latitude (rs4845490-A, R2= 0.88, ρ
= 1.7 × 10−5; rs4845327-G, R2= 0.88, ρ= 2.2 × 10−5; Fig. 2b) with
near-fixation allele frequency (0.96) observed in FIN. These findings
are in contrast to a globally common EDC SNP, rs2711, which was
not positively correlated (R2= 0.55, ρ= 8.6 × 10−3, Supplementary
Fig. 2). Together, these data reveal selective sweeps for the CEU-
LCE1A-SMCP and CEU-IVL haplotypes in European populations
that are associated with migration out-of-Africa.
CEU-IVL haplotype is associated with increased IVL gene
expression. We next determined the functional significance of the
CMS/iSAFE SNPs for the positively selected CEU-LCE1A-SMCP
and CEU-IVL haplotypes using the Genotype-Tissue Expression
(GTEx) project24. Of the four CMS/iSAFE SNPs on the CEU-
LCE1A-SMCP haplotype, only rs4845491 and rs16834728 were
identified as expression quantitative trait loci (eQTLs) that were
specific to sun-exposed skin. Their T alleles for CEU-LCE1A-SMCP
were associated with increased expression for HRNR, a gene located
outside of the haplotype (Supplementary Fig. 3). By contrast, all
seven iSAFE SNPs for the CEU-IVL haplotype were annotated as
eQTLs associated with increased IVL expression in both sun-
Fig. 1 Human evolution in the skin barrier as evidenced by multiple population-specific signals for positive selection in the epidermal differentiation
complex. a Positive selection within the EDC (hg19 [human genome]; chr1:151,904,000-153,593,700) was determined by: b clusters of SNPs with
genome-normalized (GN) composite of multiple signals (CMSGN) score > 2 with a FDR < 0.05, and c SNPs with iSAFE scores > 0.10, all shown as red dots.
Orange dots indicate SNPs 0.095<iSAFE score < 0.10. The gray shaded region indicates the region of shared evidence of positive selection in CEU (Utah of
European descent) near LCE1B-IVL. CMS scores were previously calculated for 1KGP HapMap II SNPs in CEU and JPT/CHB (Japanese in Tokyo, Japan and
Han Chinese in Beijing) populations and iSAFE scores were calculated for 1KGP Phase 3 SNPs in CEU and JPT/CHB. Here, 923 enhancer is shown as orange
bar in panel (a). kb, kilobase.
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exposed and not sun-exposed skin (Fig. 2c, representative SNP
rs4845327-G shown; and Supplementary Table 1). The SNPs were
also eQTLs for decreased expression of LCE1E and LCE1D, genes
located outside the CEU-IVL haplotype. The findings for differ-
ential IVL expression suggest a role for enhancer regulation with
population-specific variation. We previously identified and char-
acterized a strong epidermis-specific enhancer located upstream of
IVL7 (Figs. 2a and 3a). This enhancer, termed “923” is located 923
kb from the most centromeric EDC gene S100A10 and is associated
with the dynamic chromatin remodeling of the EDC and cJun/AP1
binding concomitant with EDC gene expression25. The CEU-IVL
haplotype contains the 923 enhancer and IVL. This led us to
hypothesize that the 923 enhancer modulates IVL expression
associated with positive selection.
Deletion of the 923 enhancer in mice results in decreased
expression of the proximal gene involucrin in the epidermis.
To determine the function of the 923 enhancer, we generated
knockout mice for the orthologous 923 enhancer using CRISPR/
Cas9 genome editing (Fig. 3a). Our strategy aimed to delete the
conserved noncoding element 923 with known epidermis-specific
regulatory activity7,25 and epigenetically marked by H3K27ac
histone acetylation observed in ENCODE human keratinocytes.
We targeted a larger 923 enhancer region given the H3K27ac
epigenetic mark. Two independent deletions were successfully
generated, resulting in a specific deletion of the 923 enhancer
(923del) and a large 40 kb deletion that included the 923 enhancer
and proximal genes Smcp and 2210017I01Rik (923large) (Fig. 3a,
b). At birth, 923del and 923large C57BL/6 (B6) knockout mice
were viable and did not deviate from the expected genotype ratios
for both heterozygous parental crosses (Χ2 test, α= 0.05) (Sup-
plementary Table 2). We also observed no morphological dif-
ferences or defects in barrier function under homeostatic
conditions (Supplementary Fig. 4). We next examined the
molecular impact of the 923 enhancer deletion on the skin
transcriptome. RNA-seq on 923del and 923large homozygous,
heterozygous, and wild-type (WT) newborn skins was performed
(Supplementary Tables 3 and 4, and Supplementary Data 4 and
5). Given the close proximity of the 923 enhancer to involucrin
(Ivl), we included the Ivl B6 knockout mouse26 in our analyses to
distinguish the direct effect of the loss of the enhancer from the
hypothesized loss of Ivl (Supplementary Data 6). Analysis of
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Fig. 2 Selective sweeps for CEU-LCE1A-SMCP and CEU-IVL out-of-Africa. a Phasing reveals CEU-LCE1A-SMCP and CEU-IVL haplotypes (green bars) in
CEU based on SNPs in linkage disequilibrium (r2 > 0.8) with the high CMS/iSAFE (red; rs12022319, rs4845490 [bolded], rs4845491, & rs3737861) and
iSAFE (orange; rs4845327 [bolded], rs1854779, rs7539232, rs11205132, rs2229496, rs7535306, & rs7545520) SNPs (lollipops). CEU-IVL includes IVL
and the epidermis-specific 923 enhancer, whereas CEU-LCE1A-SMCP includes LCE1A, LCE6A, and SMCP. b Direct and positive correlations between the
frequencies of rs4845490-A & rs4845327-G, and Northern latitudes reveal associations of the CEU-LCE1A-SMCP and CEU-IVL selective sweeps with out-
of-Africa migration (ρ= 1.7E-5 and 2.2E-5), respectively. Black line indicates a linear relationship (Pearson’s correlation) between allele frequency and
geographic latitude, two-sided t-test (9 degrees of freedom) with gray area surrounding the regression line representing 95% confidence intervals for the
group mean values of the latitude for each allele frequency. Pie charts of rs4845327-G allele frequency for each population are indicated on the map.
c Violin plots for rs4845327-G for CEU-IVL, an eQTL for increased IVL and decreased LCE1D and LCE1E expressions shown in not sun-exposed skin (GTEx
[V8]). Box in violin plot represents interquartile range with median (white line). Numbers in parenthesis indicate number of individuals for each genotype.
Norm. Exp., normalized expression; TPM, transcripts per million. Chi-Square p-value was calculated based on Mahalanobis distance and Bonferroni
corrected.
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Fig. 3 Deletion of the 923 enhancer in vivo identifies involucrin as a target gene via cis regulation. a Schematic of the human 923 enhancer (red) as
defined by H3K27Ac marks in NHEK (Normal Human Epidermal Keratinocytes); hg19; chr1:152,877,349-152,879,610, the conserved noncoding element
(CNE) 923 with PhastCons blocks (gray); hg19; chr1:152,878,419-152,879,075 and the orthologous deleted enhancer sequence (923del; orange) and larger
deletion (923large; blue) in the mouse with alignments to human as shown. b Generation of two 923 enhancer deletion alleles by CRISPR/Cas9 genome
editing in mice shown as dotted lines, 923del (mm10 [Mus musculus]; chr3: 92,575,843 – 92,577,094): Deletion of mouse orthologous 923 enhancer;
923large: ~40 kb deletion (mm10; chr3: 90,575,863 – 92,577,075) that includes 923 enhancer, Smcp, and 2210017I01Rik annotations. Intact flanking loxP
sites (triangles) were also successfully introduced via homologous recombination. c Volcano plots of ribosomal-zero RNA-seq differential gene expression
analyses of 923del/del (orange text), 923large/large (light blue text), and Ivl−/− (purple text) newborn mouse skins each compared to wild-type (WT) reveal
significant decreased expressions for Ivl. n= 3/genotype. FC, fold change. Statistical analysis using Limma’s generalized linear model moderated two-sided
t-tests with 22 degrees of freedom and Benjamini-Hochberg false discovery rate (FDR) corrections. Significant data points with FDR≤ 0.05 in blue are log2
fold down-regulated≤−2 and red are up-regulated ≥2. d Confirmatory qPCR validation for decreased Ivl expression for 923del/del (p= 0.030), 923large/
large (p= 0.034), and Ivl−/− (p= 0.001), and additional decreased Lce6a expression specific to 923large/large newborn mouse skins (p= 0.001) all
compared to WT mice; n= 3/genotype; Error bars ±SEM. One-way ANOVA followed by Tukey’s HSD displayed. e Proportions of allele-specific (SNP) Ivl
and Lce6a expression shown in pie charts for each mouse strain. Two SNPs per allele were measured and showed identical allele frequencies. B6 SNP
bolded, *p < 0.01, one-way ANOVA compared to WT B6/BALB mice.
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expressed genes (DEGs) in 923del/del skins, in contrast to 157 and
222 genes in 923large/large and Ivl−/− skins, respectively (FDR <
0.05, log2(FC) ≥ | 2 |; FC, fold change) (Fig. 3c and Supplementary
Fig. 5a). Strikingly, 5 of the 6 DEGs in 923del/del (Rps3a3, His-
t1h2aI, Gm16011, Rsp3a1, and Ivl) were also differentially
expressed in the same directions in 923large/large skins (Fig. 3c and
Supplementary Fig. 5b). Gm15264 was only differentially
expressed in 923del/del mice. As Rps3a1, Rps3a3, Hist1h2aI, and
Gm16011 were also differentially expressed in the same directions
in Ivl−/− skins, their observed differential expression in the 923
deletion lines are likely secondary effects associated with
decreased Ivl expression in the two enhancer deletion skins.
Together, our in vivo results identify a functional role for the 923
enhancer in the regulation of Ivl target gene expression.
The effect of the enhancer deletion on the expression of its
most proximal gene, Ivl, motivated us to further examine local
transcriptional effects with respect to only the EDC. RNA-seq
analyses of the EDC loci identified one DEG (Ivl) in 923del/del,10
in 923large/large, and 10 in Ivl−/− skin (Supplementary Fig. 6)
(FDR < 0.05, log2(FC) ≥ | 2 |). Smcp, the most proximal gene 3′ of
923 (Fig. 3b), was below our detection limits for this assay,
consistent with the low numbers of transcripts detected in whole-
skin scRNA-seq27. We validated the significance of decreased Ivl
expression in all 3 mouse lines compared to WT via qPCR
(ANOVA; Tukey post hoc, p < 0.05) (Fig. 3d). By contrast,
923large/large mouse skins also exhibited significantly decreased
expression of Lce6a, the most proximal gene 3′ of the deletion,
which was not observed in the other 2 mouse lines. This suggests
the presence of an additional as yet uncharacterized enhancer
region for Lce6a that was also deleted in the 923large allele.
Deletion of 923 enhancer affects the chromatin landscape in
the EDC. We next sought to determine the effect of the 923
enhancer deletion on the EDC chromatin landscape using ATAC-
seq (assay for transposase accessible chromatin using
sequencing)28. Six differentially accessible regions (DARs) were
found in both 923del/del and 923large/large keratinocytes compared
to WT. Interestingly, three of these shared DARs were within or
near (<250 kb) the EDC with two less-accessible DARs and one
more-accessible DAR found in both 923del/del and 923large/large
keratinocytes (Supplementary Fig. 7 and Supplementary Tables 5
and 6) (FDR < 0.05, log2(FC) ≥ | 2 |). Although none of the shared
DARs correspond to differential changes in gene expression as
determined by RNA-seq, our findings demonstrate an effect for
the loss of the 923 enhancer on opening local EDC chromatin
accessibility in newborn keratinocytes. Together, both enhancer
deletion lines demonstrate a requirement for the enhancer to
positively regulate Ivl, and additionally for the 923large allele for
Lce6a expression, and facilitate local chromatin accessibility.
923 enhancer regulates Ivl target gene expression in an allele-
specific (cis) manner. We next determined if the 923 enhancer
regulates gene expression in cis. To do this, we performed allele-
specific gene expression assays for Ivl and Lce6a in hybrid mouse
skin. Allele-specific Ivl and Lce6a transcripts were distinguished
using two informative SNPs for either B6 or BALB/cBYJ (or
BALB) allele in hybrid B6;BALB mouse tissue. Targeted
sequencing of Ivl cDNA from 923delB6/BALB and 923largeB6/
BALB hybrid mouse skin revealed a significantly lower propor-
tion of B6 transcripts from the 923del and 923large alleles (13%)
compared to the proportion of B6 transcripts from the WT allele
observed in hybrid control B6/BALB mice (50%) (Fig. 3e)
(ANOVA, Tukey post hoc, p < 0.01). Moreover, a significantly
lower proportion of Lce6a B6 transcripts (3%) was observed in
923largeB6/BALB hybrid skin compared to 42% and 40% observed
in the hybrid control B6/BALB and the 923delB6/BALB skin,
respectively (ANOVA, Tukey post hoc, p < 0.01). This further
supports the hypothesis for the loss of an additional regulatory
enhancer in the 923large allele to regulate allele-specific Lce6a
expression. Together, our genetic findings identify cis regulation
by the 923 enhancer for Ivl, thus establishing a 923 enhancer:Ivl
regulatory module for the epidermis.
The human 923 sequence enhances expression from the IVL
promoter with both elements exhibiting population-specific
regulatory activities. We next translated this new functional
knowledge of the 923 enhancer:Ivl regulatory module found in
mice to determine the genomic sequences and variants that drive
increased IVL expression in the positively selected CEU-IVL
human haplotype. Enhancer rs4845327, promoter rs1854779, and
intronic rs7539232 and rs11205132 were identified as positively
selected signals by iSAFE and are IVL eQTL alleles specific to
CEU-IVL (Fig. 4a and Supplementary Table 1). We hypothesized
increased regulatory activity within the promoter and enhancer
for CEU-IVL in comparison to common JPT/CHB and YRI
haplotypes. We performed luciferase assays to assess regulatory
activities for population-specific IVL promoters with and without
the enhancer for CEU-, JPT/CHB-, and YRI-IVL. Clones for IVL
promoter alleles included the first noncoding exon and intron of
known collective regulatory activity29. The CEU-IVL promoter/
intron allele exhibited significantly higher luciferase activity than
the JPT/CHB and YRI alleles in both proliferating and differ-
entiated keratinocyte cell culturing conditions (Proliferating: CEU
vs. JPT/CHB p= 0.003, CEU vs. YRI p= 0.025; Differentiated:
CEU vs. JPT/CHB p= 0.008, CEU vs. YRI p= 0.001), consistent
with the GTEx annotated SNPs for increased IVL expression
(Figs. 4b and 2c). The addition of the respective population-
specific 923 enhancer resulted in a further increase in luciferase
reporter activities for all tested alleles compared to the promoter/
intron only, and higher in differentiated cells where IVL is
endogenously expressed in skin tissue (Fig. 4b). However,
decreased luciferase activity for the cloned JPT/CHB enhancer/
promoter/intron allele was observed in comparisons to CEU and
YRI alleles (Proliferating: CEU-JPT/CHB, p= 0.003; YRI-JPT/
CHB, p= 0.024; Differentiated: CEU-JPT/CHB, p= 0.047; YRI-
JPT/CHB, p= 0.051) (Fig. 4b). The JPT/CHB allele is associated
with relatively decreased IVL expression as shown in GTEx
(Supplementary Fig. 8 and Supplementary Table 7). Together, our
results identify increased regulatory activity for the IVL pro-
moter/intron allele with an additive effect by the enhancer for the
positively selected CEU-IVL haplotype.
We next sought to determine differential transcription factor
binding for the reference and alternate SNP alleles that underlie
the observed regulatory activities for the population-specific IVL
alleles (Supplementary Table 8). Using multiple transcription
factor motif analyses, we identified four SNPs that were predicted
to impact differential binding by keratinocyte-specific transcrip-
tion factors. The SNPs included the two positively selected iSAFE
SNPs, IVL enhancer (rs4845327) and the IVL promoter
(rs1854779), as well as two additional SNPs in the IVL enhancer
(rs1974141) and first intron (rs7517189) (Fig. 4c). ZNF263 is
predicted to bind to CEU 923 enhancer rs1974141-A in contrast
to MAZ binding to the alternate rs1974141-G (JPT/CHB),
suggesting either higher activation by ZNF263 or loss of a
MAZ-mediated repressive effect for the relative increased IVL
expression and enhancer activity observed in the CEU cloned
allele. IRF1 is predicted to bind to the positively selected enhancer
SNP, rs4845327-G, and negatively affect SOX10 binding for the
alternate T allele, whereas NFIC is predicted to bind to the
positively selected promoter SNP, rs1854779-T, in contrast to
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SPI1 for the alternate rs1854779-C allele. RELA is predicted to
bind to intronic rs7517189-C compared to GATA3 for the G
allele. Using publicly available ENCODE ChIP-seq datasets, we
demonstrated preferential binding in vivo for ZNF263 (A), MAZ
(G), NFIC (T), and SPI1 (C) to the predicted alleles with
polymorphic sites (Supplementary Fig. 9 and Supplementary
Table 9). These findings for allele-specific, transcription factor
binding at several loci in different cell types are consistent with
the following allele-specific findings that we observe for the
positively selected CEU-IVL haplotype: (1) increased IVL
expression, (2) increased regulatory activities for the enhancer
and promoter, and (3) preferential ZNF263 and IRF1 predicted
binding to rs1974141-A and rs4845327-G in the enhancer and
NFIC binding to rs1854779-T in the promoter. In summary, we
identify positive selection for a cis-regulatory module for
increased IVL that underwent a selective sweep out-of-Africa
and highlights human skin barrier adaptation.
Discussion
Our work thus far has identified recent skin barrier evolution in
modern human populations, having discovered several
population-specific signals of positive selection within the EDC
and selection for two neighboring haplotypes, LCE1A-SMCP and
IVL in CEU. The association of the CEU-IVL haplotype with
relatively increased IVL gene expression and the overlap to the
known epidermis-specific enhancer 923 led us to examine a
functional role for the 923 enhancer to regulate Ivl expression
in vivo. Deletion of the orthologous mouse 923 enhancer via
CRISPR/Cas9 genome editing identified Ivl as the primary target
gene of 923 with regulation in cis, thus establishing a 923
enhancer-Ivl gene regulatory module. The functional significance
of this genetic module in humans was further revealed with our
discoveries of population-specific 923 enhancers that “boosted”
regulatory activity. Together, we establish the significance of a
paradigmatic regulatory module for a cis-regulatory enhancer/
target gene in human evolution.
Our understanding of the molecular mechanisms that drive
enhancer activity30,31 and the comprehensive genomic elucida-
tion of putative enhancers for a vast array of tissue types, as well
as single cells, has exponentially grown since the inception of the
“enhancer” concept in 198132. Yet, we are challenged to embark
on more rigorous investigations to functionally validate enhan-
cers and correctly assign their predicted target genes31. Even
more challenging is the growing body of recent reports demon-
strating a lack of phenotypes for enhancer deletions, even for
Fig. 4 Population-specific 923 enhancer: IVL promoter/intron alleles and eQTLs impact regulatory activity. a Schematic of population-specific human
923 enhancer (red), IVL promoter (light blue), 1st exon, and intron (dark blue) alleles with IVL eQTLs. Positions of variants not to scale. Colored boxed
variants are associated with relatively lower IVL expression levels to human reference. Positively selected iSAFE SNPs for CEU in orange. b Luciferase
assays of population-specific alleles for the IVL promoter/intron+ respective enhancer reveals that the CEU promoter/intron allele has the highest
regulatory activity (Proliferating: p= 0.003 vs. JPT/CHB; p= 0.025 vs. YRI; Differentiated: p= 0.008 vs. JPT/CHB; p= 0.001 vs. YRI). The addition of the
enhancer confers higher reporter expression with more activity in CEU (p= 0.003) and YRI (p= 0.024) than JPT/CHB and especially in differentiated cells
for CEU vs. JPT/CHB (p= 0.047). Mean ± SEM of n independent experiments (n= 3, IVL promoter/intron) and (n= 4, 923 enhancer+ IVL promoter/
intron), one-way ANOVA followed by Tukey’s HSD. c Position weight matrices (PWM) for candidate transcription factor binding motifs in reference and
alternate alleles at rs1974141, rs4845327, rs1854779, & rs7517189 associated with population-specific regulatory activity. Strand sequence with SNP
included for comparison to PWM.
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putative developmental enhancers, suggesting enhancer redun-
dancy consistent with the ENCODE findings of 2–3 enhancers
per target gene33–35. As Ivl expression was not completely lost in
our enhancer knockout mice, there is likely redundancy in reg-
ulation of Ivl yet we have firmly established the 923 enhancer as a
prominent proximal enhancer. In keratinocytes, 5C studies
identified physical interactions between the Ivl promoter and
enhancers located in the first topologically associated domain
(TAD) of the EDC, presenting additional putative regulators36.
Our discovery for the 923 enhancer to regulate Ivl expression was
premised on extensive previous analyses of the 923 enhancer,
where we identified its sequence conservation across mammalian
phylogeny, DNaseI hypersensitivity in primary keratinocytes,
regulatory activity observed in reporter assays7, tissue-specific
(epidermis) activity using transgenic mice, and physical chro-
matin looping contacts determined by chromatin conformation
capture studies25. Such studies provide a framework to prioritize
such ongoing and future enhancer in vivo deletion studies. Fur-
thermore, our CRISPR/Cas9 methodology led to the serendipi-
tous generation of a larger deletion (923large), which displayed
decreased Lce6a expression that generates the hypothesis for
additional enhancers that were deleted in the 923large allele.
Interestingly, the backbone of the CEU-IVL haplotype appears
to have emerged in Africa and rose to near-fixation frequency in
CEU and other European populations. This selective sweep for
CEU-IVL is associated with increased IVL expression, which we
tied to the promoter/intron variants with an additive effect upon
the inclusion of the enhancer allele. The effects were further
predicted to impact preferential transcription factor binding for
ZNF263, IRF1, and NFIC in contrast to MAZ, S0X10, and SPI1
binding in the alternative alleles for rs1974141 and rs4845327
enhancer, and rs1854779 promoter SNPs, and for which pre-
ferential binding for these TFs (transcription factors) at single
polymorphic sites have been observed in ENCODE ChIP-seq
data. Future experiments are needed to isolate and further
determine the functional effects of each SNP on IVL expression
and even on other cell types. In fact, rs1854779 was recently
determined to be associated with white blood cell count and was
discovered by including diverse human populations to compre-
hensively determine phenotypic traits37. This, together with our
human evolutionary findings, generates a hypothesis for a human
skin diversity SNP to rapidly evolve and modulate the functional
interface of the skin and immune systems.
Our discovery of enhancer variation for human skin barrier
function further contributes to a growing body of research that
highlights selective events in human history targeted at enhan-
cers, such as lactase persistence38–42 and immune function43.
Furthermore, our finding for enhancer evolution further supports
genetic innovation for human skin evolution that until now has
been reported for only a few genes in the EDC, including IVL44.
IVL has undergone extensive evolution in primates, with recent
and continuing expansion of the number of repeats in human
IVL45–52. However, targeted deletion of the Ivl gene in mice
revealed no overt phenotype in barrier-housed conditions26,
similar to our 923del/del and 923large/large homozygous mice
(Supplementary Fig. 4). Together, this supports a tolerance for
decreased, and even lack of, Ivl in barrier-housed conditions,
consistent with human population-specific selection for differ-
ential IVL expression that warrants further investigation. The
findings for a selective sweep for increased IVL observed in
European populations that live in Northern latitudes suggests a
possible link between cutaneous vitamin D production and IVL
expression as a mechanism of environmental adaptation for the
skin barrier. Vitamin D is known to stimulate the differentiation
of keratinocytes53–55 and promote the expression of IVL56,57; it is
possible that high rates of vitamin D deficiency in modern
populations58,59 could contribute to reduced skin barrier integrity
and, subsequently, disease states including asthma60.
Selective sweeps for haplotypes, CEU-LCE1A-SMCP with
increased HRNR and CEU-IVL with increased IVL expressions,
suggest a benefit for higher protein dosage for the evolving skin
barrier. This notion is supported by (1) the absence of common
deleterious (albeit truncating) variants in strong linkage within
these haplotypes and (2) the highly repetitive nature of HRNR
and IVL that lengthens the protein structures observed across
mammalian and primate phylogenies45–52,61 and anticipated
trajectories in humans. The functional benefits for increased
HRNR and IVL have yet to be functionally determined, yet it can
be speculated that protein dosage modulation provides an inno-
vative strategy to calibrate skin barrier function, i.e., permeability,
to the environment. Indeed, weakened epidermal barrier function
is a hallmark of atopic dermatitis, a common inflammatory dis-
ease, owing to the discovery for >100 loss-of-function variants for
the highly repetitive FLG gene that are population-specific, and
an increase in prevalence worldwide62.
In summary, our results highlight the significance of genetic
variation attributed to differential gene expression in a
population-specific manner and heighten our awareness for
human population-specific evolution of the epidermis. Further-
more, our work provides a framework with which we can
examine genetic variation in enhancer:target gene modules for
recent adaptive traits.
Methods
CMS and iSAFE analyses. CMS scores for all SNPs in the EDC (hg18;
chr1:150,198,268-151,892,013) in CEU, YRI, and JPT/CHB populations (n= 90
individuals per population) were downloaded (https://www.broadinstitute.org/
cms/results; download date August 17, 2015). p-values were calculated for the
genome-normalized CMS scores using pnorm in R. Benjamini-Hochberg FDR was
calculated for each population using the p.adjust function, method= “BH” in the
fdrtool package in R. iSAFE (https://github.com/alek0991/iSAFE)21 was used to
identify positive selection in 1KGP Phase 3 phased data (http://ftp.1000genomes.
ebi.ac.uk/vol1/ftp/release/20130502) (hg19; chr1:151,896,000-153,612,000). Sample
cases were defined as all subjects belonging to the population of interest (CEU, FIN,
IBS, YRI or JPT, and CHB) and sample controls defined as subjects belonging to all
other superpopulations. All other arguments were run using default settings.
Haplotype block construction and LD analysis. Haplotypes were identified using
LDLink (https://ldlink.nci.nih.gov) by querying the LDproxy module for the SNP
with the highest CMS score in the relevant population(s). Haplotypes were defined
as the set of proxy variants with r2 ≥ 0.8. Pairwise and small-scale analyses of LD
were performed using the LDpair module, again defining LD as R2 ≥ 0.8.
Global allele frequency and eQTL analysis. Allele frequencies of EDC SNPs from
the twenty-six 1KGP populations were obtained from Ensembl v. 8163,64. Geo-
graphical latitude for each population was determined by the latitude of the city
from which 1KGP, ACPOP (Northern Sweden), Genome of the Netherlands
release 5, Genetic variation in the Estonian population, and the Danish reference
pan genome population data for tagging SNP rs4845327 were collected. The
relationship between latitudes and allele frequencies was analyzed using linear
regression using the lm function in R. The direction and strength of the correlation
between allele frequency and latitude was determined using Pearson’s correlation
coefficient (ρ) using the cor function in R. Geographic plots for the global dis-
tribution of allele frequency was generated using ggplot2 in R. SNPs were queried
as eQTLs in sun-exposed or not sun-exposed skins using GTEx portal (http://www.
gtexportal.org; V8 release).
Generation of 923 enhancer knockout alleles in mice by CRISPR/Cas9 gen-
ome editing. Deletion of the 923 enhancer was targeted using two small guide
RNAs to facilitate Cas9-mediated double-stranded breaks on either side of the
orthologous mouse 923 enhancer sequence. LoxP insertions at these flanking
sgRNA-targeted sites were generated using two single-stranded oligodeox-
ynucleotides (ssODNs), containing loxP sites with specific 80 bp homology arms on
either side of loxP and restriction enzyme sites (SphI for 5′ end, HindIII at 3′ end),
which were simultaneously introduced via site-directed homologous recombination
(Integrated DNA Technologies, Coralville, IA). Sequences of sgRNAs, ssODNs, and
mouse alleles are listed in Supplementary Information (Supplementary Table 10).
Three rounds of injection in 779 zygotes were performed having confirmed target
specificity using in vitro pilot studies prior to zygote injection. Founders were
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initially screened for large deletions via PCR using flanking primers designed
outside the homology arms and 5′ and 3′ loxP-specific primers that were resolved
on 1% agarose gel electrophoresis. Of the 779 C57BL6/6XCBA hybrid zygotes
injected, 80 F0 newborns were recovered, of which 75 survived to weaning age.
Seven out of 80 mice whose 923 allele size deviated from the WT allele were
identified via PCR (8.75% targeting efficiency) with further analysis by Sanger
sequencing. Two 923 enhancer knockout alleles were confirmed. The 923del allele
contains an ~1250 bp deletion of the 923 enhancer and the 5′ loxP site. The 923large
allele includes the 923 deletion flanked by both 5′ and 3′ loxP sites and a 40 kb
deletion between proximal genes Lce6a and 923, including the genes Smcp and
2210017I01Rik. All mice were group-housed in cages with bedding and nesting
material in pathogen-free, barrier facilities (65–75 °C and 40–60% humidity) with a
12 h light/dark cycle at Washington University School of Medicine (St. Louis, MO).
All animal procedures were approved by the Division of Comparative Medicine
Animal Studies Committee at Washington University in St. Louis School of
Medicine. All animal work was conducted in accordance with the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health. Morning
observation of a vaginal plug was designated as embryonic day (E) 0.5. Both 923del
and 923large mouse lines were backcrossed at least 7 times to the C57BL/6 back-
ground to generate isogenic strains and to exclude potential off-target effects
arising from CRISPR/Cas9 editing. Measurements for each of the molecular assays
for the mice were taken from distinct samples. A list of all primers used throughout
this study are provided in Supplementary Information (Supplementary Table 11).
Histology. Dorsal skin was excised from 8-week-old mice and preserved in 4%
paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA) prior to paraffin
sectioning. Sections were stained with hematoxylin and eosin by the Washington
University Developmental Biology Histology Core. Slides were imaged on a Nikon
Eclipse 80i brightfield microscope (Nikon, Tokyo, Japan).
Dye penetration barrier assays. Barrier assays were performed with X-gal
solution incubations for at least 4 h at 37 °C65. Images were captured on a
CanoScan 5600 F scanner (Canon, Melville, NY).
Cornified envelope preparations. Epidermis (cut into 1 cm2 pieces) was incu-
bated at 95 °C in a solution of 2% SDS to obtain cornified envelopes in a single-cell
suspension. The suspension was placed on a slide and inspected using phase
contrast light microscopy.
Trans-epidermal water loss assay. TEWL was measured on the abdominal skin
surface of newborn mice using the nail attachment of a VapoMeter (Delfin
Technologies, Kuopio, Finland, courtesy of Jeff Miner).
Immunofluorescence. Fresh sections were fixed in 4% paraformaldehyde (Elec-
tron Microscopy Sciences, Hatfield, PA) prior to permeabilization with 0.1% Triton
X-100 and subsequent antibody incubation. The following antibodies were used for
immunofluorescence: rabbit IVL (4b-KSCN, 1:200) and chicken K14 (5560, 1:500)
custom antibodies (courtesy of J. Segre), goat anti-rabbit (Alexa Fluor 488 #A-
11008, 1:500), and goat anti-chicken (Alexa Fluor 594 #A-11042, 1:500) IgG
antibodies (Life Technologies, Frederick, MD), and DAPI counterstained (Slow-
Fade Gold antifade reagent) (Life Technologies). Fluorescent microscopy was
performed on Zeiss AxioImager Z1 and captured with AxioCam MRc and Axio-
vision software (Carl Zeiss, Stockholm, Sweden), or imaged on a DMI3000 B
(Leica, Wetzlar, Germany) and captured with the QIClick camera (QImaging,
Surrey, BC, Canada).
RNA-seq. Total RNA from whole skin was isolated by TriZol extraction (Life
Technologies, Frederick, MD). Ribo-zero (ribosome-depleted) RNA sequencing
libraries were prepped according to the manufacturer’s library kit protocol,
indexed, pooled, and sequenced on Illumina HiSeq 3000 (1X 50 bp) by the
Washington University Genome Technology Access Center.
Basecalls and demultiplexing were performed with Illumina’s bcl2fastq software
v2.20 with a maximum of one mismatch in the indexing read. RNA-seq reads were
then aligned to the Ensembl release 96 top-level assembly with STAR version
2.0.4b. Gene counts were derived from the number of uniquely aligned
unambiguous reads by Subread:featureCounts version 1.4.5. Sequencing
performance was assessed for the total number of aligned reads, total number of
uniquely aligned reads, and features detected. The ribosomal fraction, known
junction saturation, and read distribution over known gene models were quantified
with RSeQC version 2.3. All gene counts were then imported into the R/
Bioconductor package EdgeR version 3.22.0, and TMM normalization size factors
were calculated to adjust for samples for differences in library size. Ribosomal
genes and genes not expressed in the smallest group size minus one samples greater
than one count-per-million were excluded from further analysis. The TMM size
factors and the matrix of counts were then imported into the R/Bioconductor
package Limma version 3.36.5. Performance of the samples was assessed with
Spearman correlations, a multi-dimensional scaling plot, and hierarchical
clustering. Weighted likelihoods based on the observed mean–variance relationship
of every gene and sample were then calculated for all samples with the
voomWithQualityWeights. The performance of all genes was assessed with plots of
the residual standard deviation of every gene to their average log-count with a
robustly fitted trend line of the residuals. Differential expression analysis was then
performed to analyze for differences between conditions and the results were
filtered for only those genes with Benjamini-Hochberg false-discovery rate adjusted
p-values ≤ 0.05, and a log2(FC) ≥ | 2 |.
The R/Bioconductor package heatmap3 version1.1.6 and Pathview version
1.18.2 was used to display heatmaps or annotated KEGG graphs across groups of
samples for each GO term or KEGG pathway, respectively, with a Benjamini-
Hochberg false-discovery rate adjusted p-value less than or equal to 0.05.
Real-time qPCR on cDNA (generated using SuperScript II reverse transcriptase
(Thermo Fisher Scientific) using TaqMan Gene Expression Assay was performed in
triplicate (Applied Biosystems, Life Technologies, Carlsbad, CA) and normalized to
β2-microglobulin. Only CT values with single peaks on melt-curve analyses were
included.
ATAC-Seq. ATAC-seq was performed on 75,000 epidermal cells from each mouse
with variations28. Cells were lysed for 5 min in 37.5 μl ice-cold buffer (10 mM
TrisHCl, 10 mM NaCl, 2 mM MgCl2, 0.5% IGEPAL CA-630). Cells were then
pelleted at 500g (4 °C) for 15 min. Lysis buffer was replaced with transposition
reaction mix (12.5 μl TD (2X reaction buffer from Nextera Kit, Illumina, San Diego
California, USA), 2.5 μl TDE1 (Nextera Tn5 Transposase from Nextera kit, Illu-
mina), and 10 μl H2O) and samples were incubated for 1 h at 37 °C. Samples were
purified using Qiagen MinElute PCR Purification Kit (Qiagen, Valencia, CA) and
PCR-amplified. Adapter dimer bands were removed using AMPure XP bead
treatment (Beckman Coulter, Brea, CA). All Samples exhibited the expected
nucleosome periodicity as assayed by High Sensitivity ScreenTape (Agilent Tech-
nologies, Santa Clara, CA). Samples were sequenced via Illumina HiSeq2500 (2X
50 bp). An average of 93.4% of the reads were mapped with 14.3–39.8 million
qualified reads per sample with only an average of 6.8% mitochondrial reads
(Table S18). Prior to sequencing, all samples exhibited the expected periodicity of
insert length and were enriched for reads at transcription start sites. ATAC-seq
data were processed using the ENCODE ATAC-seq processing pipeline, using
Caper with Conda (https://github.com/ENCODE-DCC/atac-seq-pipeline)66. Reads
were mapped using Bowtie2 version 2.3.5.1, and filtered to remove unmapped
reads, duplicates, and reads mapping to chrM. Peaks were called on each replicate
using MACS267. Biological replicates were included if both the rescue and self-
consistency IDR values per genotype were below (or very near to) 2 (Supple-
mentary Table 12). Differential accessibility was assessed using EdgeR68 within the
DiffBind R package version 2.12.0 (http://bioconductor.org/packages/DiffBind/)
(FDR < 0.5, log2(FC) ≥ | 2 |).
Allele-specific gene expression. RNA from newborn whole skins was isolated as
described above from C57Bl6 and BALB/cBYJ wild-type mice and from [C57Bl6]/
[BALB/cBYJ], [923del/[BALB/cBYJ], and [923large/[BALB/cBYJ] hybrid mice. RNA
was DNaseI treated and reverse transcribed into cDNA using Invitrogen Super-
scriptII Reverse Transcriptase (Invitrogen, Carlsbad, CA); 260 bp amplicons tar-
geting the Ivl, 2210017l01Rik, and Lce6a genes were amplified from cDNA using
NEBPhusion High Fidelity PCR 2X master mix (New England BioLabs, Ipswich,
MA) (Amplicon Sequences in Supplementary Table 11). PCR products were
purified on Qiagen QIAquick PCR columns (Hilden, Germany), A-tailed with
1 mM dATP and NEB Taq polymerase for 20 min at 72 °C (New England BioLabs,
Ipswich, MA) followed by an additional column purification on Qiagen MinElute
columns. Next-generation sequencing-compatible adapters were ligated to A-tailed
PCR products in molar excess using the LigaFast DNA ligase kit (Promega,
Madison, WI) at room temperature for 20 min. Products were size-selected using
Agencourt AMPure XP beads (Beckman Coulter, Brea, CA) at 1.2X product
volume to remove excess adapter. Adapter-ligated products were quantitated using
Qubit dsDNA High Sensitivity Assay kit (Life Technologies, Carlsbad, CA). To
determine appropriate PCR amplification cycle number to avoid over amplifica-
tion, quantitative PCR was performed using 2X NEB Phusion High Fidelity PCR
master mix, 0.5 μM PCR primer1, 0.01 μM PCR primer2, 0.5 μM unique Index
Primer, 100X SYBR Green and 50X ROX Dye, and 2 ng DNA in 10 μl. PCR cycle
number for each template was determined by identifying the cycle where ¼ max
fluorescence was reached; 10 ng of each library was amplified using the same
reaction, without SYBR and ROX, scaled up to 50 μl. Amplified libraries were size-
selected again to remove any remaining adapter dimer using 1X concentration of
AmPure beads. All libraries were pooled at equal molar ratio and sequenced as a
spike-in to a 2 × 150 bp MiSeq sequencing run, averaging 154,000 reads per sample.
Demultiplexed reads were mapped using Bowtie2 version 2.3.5.1 and visualized
using the IGV viewer. The proportion of nucleotides at each informative SNP in
the amplicon was calculated by IGV. Primers are listed in Supplementary Infor-
mation (Supplementary Table 11).
Luciferase assays. Population-specific alleles for the IVL promoter, noncoding
first exon, and intron were cloned from human gDNA by PCR using primers 5′-G
GATCCGATAGGTTCTAGGGGTATAGTGG/5′-AAGCTTCTTAGAAGCTA
CTGTCAACCTG. PCR products were digested with BamHI and HindIII and
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-22821-w ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:2557 | https://doi.org/10.1038/s41467-021-22821-w | www.nature.com/naturecommunications 9
cloned into the BglII/HindIII site in pGL3 (Promega) to yield pGL3-IVLpromoter
and confirmed by Sanger sequencing. The Gateway cassette B was then cloned into
the SmaI site to yield pGL3-IVLpromoter-GW. The 923 enhancer region was
amplified from human gDNA using primers 5′- GGGGACCACTTTGTACAAG
AAAGCTGGGTGAAGAACAGTGAATTTTACGACC/5′- GGGGACAAGTT
TGTACAAAAAAGCAGGCTAGACATTCTGCTGCTGGACA and introduced
into pDONR221 by BP recombination using BP Clonase II (Invitrogen, Thermo
Fisher Scientific). Haplotype-specific variants were confirmed by Sanger sequen-
cing. Enhancer alleles were then introduced into pGL3-IVLpromoter-GW by LR
recombination using LR Clonase II (Invitrogen, Thermo Fisher Scientific) to yield
pGL3-IVLpromoter-923. Enhancer alleles were then introduced to pGL3 by LR
recombination. Luciferase reporter assays were performed in the mouse SP-1
keratinocyte cell line with measurements performed at 48 and 72 h post-
differentiation for proliferating and differentiated cells, respectively, using a Glo-
max luminometer (Promega)7,25. Significance was determined using one-way
ANOVA followed by Tukey’s HSD.
Transcription factor binding predictions. Transcription factor binding prediction
was determined using transcription factor motifs considering the position and
weight of the nucleotide for a given binding motif and evidence of transcription
factor expression in keratinocytes (Human Protein Atlas)69,70 and ENCODE ChIP-
seq binding (where possible). Both reference and alternate nucleotides for a given
SNP were rigorously queried and centered at position 25 in a 50 bp window were
analyzed with PROMO 3.071,72 and ConSite (http://consite.genereg.net/cgi-bin/
consite). PROMO 3.0 with TRANSFAC version 8.3 considered only human sites
and human factors with 15% maximum matrix dissimilarity rate and ConSite
utilized the option for all transcription factor profiles with a minimum specificity of
10 bits and transcription factor score cutoff of 80% in a single sequence. JASPAR73
with a relative profile score threshold of 80% was used to analyze each SNP allele
(reference and alternate independently) centered at position 15 in a 30 bp window.
HAPLOREG v.474 was queried for a given SNP rsID. ENCODE ChIP-seq matrix
considered Homo sapiens transcription factors that were present at the SNP
location in skin cell lines, keratinocyte or foreskin keratinocyte primary cell lines,
or suprapubic skin tissue75. Transcription factors predicted were checked for
positive antibody staining in keratinocytes from primary data in the Human
Protein Atlas69,70. We interpreted transcription factor binding that satisfied JAS-
PAR plus either ConSite, PROMO 3.0, or HAPLOREG predictions.
Allele-specific ChIP-seq analysis. All ChIP-Seq data, including IDR thresholded
peaks bed and bam alignment files were downloaded from ENCODE (accessions
list, Table S19). Variant calls in vcf format were downloaded from ENCODE
(HepG2: ENCSR319QHO, K562: ENCSR053AXS), the Platinum Genomes
project76, and the HEK293 genome project (http://hek293genome.org/v2/)77 and if
necessary converted to hg38 using liftOver. Variants were further filtered to only
include heterozygous variants. Sequences for each ChIP-seq peak were extracted
using bedtools and the hg38 UCSC genome reference. Motifs for each TF from
JASPAR 202073 (MAZ: MA1522.1, NFIC: MA0161.1, SPI1: MA0080.1, ZNF263:
MA0528.2) and used FIMO (part of the MEME suite v5.3.3)78 were downloaded to
search for occurrences of each motif with max-stored-scores set to 1E-8. Since the
appropriate p-value threshold is dependent on the motif length and information
content, p-values were scanned for each motif search across the values 1E-5, 5E-4,
1E-4, 5E-3, and 1E-3. For each motif, the p-value was set based on whether there
was an average of 0.5–1 motifs found per ChIP-seq peak across each of the datasets
for a given TF (Supplementary Table 13). Bedtools (v2.26.0, https://bedtools.
readthedocs.io/) was used to overlap identified motifs with heterozygous SNPs
using the variant calls (.vcf file) from the appropriate cell line. Samtools (v1.3.1,
http://www.htslib.org/) view with the -L flag was used next to extract all alignments
that overlapped identified ChIP-seq peaks. Aligned reads were overlapped to
identify each SNP, manually curated to ensure the SNP corresponded to the
queried variant, and counted for the number of reads supporting each base. Fur-
ther, only SNPs with coverage ≥5 and within 50 bp of the peak center were
retained. Results from IRF1 and RELA are not included since no SNPs met these
criteria.
Ethics. Cloned human alleles was obtained from prior human research79 according
to the Declaration of Helsinki with provided written informed consent. The study
was approved by the Washington University in St. Louis Institutional Review
Board (#201109075).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All data supporting the findings of this study are available within this article and
the Supplementary Information. Raw RNA and ATAC sequencing data are available in
NCBI Gene Expression Omnibus (GEO) using the accession code GSE158870. The
following ENCODE ChIP datasets were used: GM12878-MAZ (ENCSR903MVU,
ENCSR000DZA), HEK293-MAZ (ENCSR290SSQ), HepG2-MAZ (ENCSR700PNE,
ENCSR000EDN), K562-MAZ (ENCSR163IUV, ENCSR643JRH), HEK293-ZNF263
(ENCSR000EVD), HepG2-ZNF263 (ENCSR313MMD), K562-ZNF263
(ENCSR000EWN), GM12878-NFIC (ENCSR000BRN), K562-NFIC (ENCSR796ITY),
GM12878-SPI1 (ENCSR000BGQ), and K562-SPI1 (ENCSR000BGW). Links to the
ENCODE datasets and the reporting summary are available in the Supplementary
Information. Source data are provided with this paper.
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